Key Highlights
- Viz.ai partners with Addario Lung Cancer Medical Institute (ALCMI) to enhance lung cancer detection.
- AI integration aims to improve clinical workflows from nodule workup to precision medicine.
- Focuses on addressing rural and community healthcare disparities with AI-driven treatments.
- Collaboration will boost patient engagement and access to advanced care and research.
Source: Business Wire
Notable Quotes
- “We are pleased to partner with ALCMI to improve the standard of care for lung cancer patients. Our partnership will help healthcare providers coordinate and deliver the needed care at the right time and increase patient access to life-saving treatments.” — Chris Mansi, MD, CEO and Co-founder at Viz.ai
- “AI represents an incredible opportunity to improve the speed and quality of our research, and we’re proud to partner with Viz.ai, which has led the way in the medical application of this technology.” — Richard Erwin, Executive Director at ALCMI
- “It’s critical that we utilize every available tool and resource to diagnose and treat this disease as early as possible. We intend to utilize the power of AI to assist in treating lung cancer patients earlier with more precise diagnosis and treatment regimens.” — Bonnie Addario, Co-founder at ALCMI
SoHC's Take
This partnership between Viz.ai and ALCMI marks a significant step forward in lung cancer care, particularly by leveraging AI to enhance early detection and streamline clinical workflows. The integration of Viz.ai’s AI-powered care coordination with ALCMI’s research expertise will not only improve patient outcomes but also address healthcare disparities in underserved communities. This collaboration is poised to redefine how lung cancer is diagnosed and treated, potentially making it a more survivable disease.
